As molecular testing becomes the standard of care for many cancers, nurse navigators have an important role to play ensuring molecular testing of suitable patients, providing patient education, and managing of patient expectations.

Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.

Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.

Multiplex gene testing of diverse patients has found that patients who test positive advise relatives to test, "suggesting that participants understood the implications of test results," according to results of a planned interim analysis of a prospective trial presented at the ASCO 2016 Annual Meeting.

A stool DNA test for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the highest rates of colorectal cancer in the world, according to a recent study.

A new study has uncovered four new genetic variants associated with increased risk of testicular cancer. Testing for these and all 21 previously identified variants using genetic sequencing identified men at higher risk of testicular cancer.

Use of the 21-gene recurrence test score was associated with lower chemotherapy use in high-risk patients and greater use of chemotherapy in low-risk patients compared with not using the test score among a large group of Medicare beneficiaries, according to a recent investigation.

New research indicates that many genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the person.